诚达药业12月24日获融资买入1804.28万元，融资余额2.63亿元

Group 1 - The core viewpoint of the news is that Chengda Pharmaceutical's stock performance and financial metrics indicate a mixed outlook, with significant financing activity and a notable decline in net profit despite revenue growth [1][2]. Group 2 - On December 24, Chengda Pharmaceutical's stock fell by 0.86%, with a trading volume of 151 million yuan. The financing buy-in amount for the day was 18.04 million yuan, while the financing repayment was 12.14 million yuan, resulting in a net financing buy of 5.90 million yuan. The total financing and securities balance reached 263 million yuan [1]. - The financing balance of Chengda Pharmaceutical is 263 million yuan, accounting for 4.11% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - As of December 24, there were no shares repaid or sold in the securities lending market, with a securities lending balance of 0 yuan, which is also at a high level compared to the past year [1]. Group 3 - As of September 30, the number of shareholders for Chengda Pharmaceutical was 12,700, a decrease of 8.58% from the previous period. The average circulating shares per person increased by 36.16% to 8,577 shares [2]. - For the period from January to September 2025, Chengda Pharmaceutical achieved operating revenue of 285 million yuan, representing a year-on-year growth of 16.95%. However, the net profit attributable to the parent company was 16.77 million yuan, a decrease of 58.47% year-on-year [2]. Group 4 - Chengda Pharmaceutical has distributed a total of 133 million yuan in dividends since its A-share listing, with cumulative distributions of 89.62 million yuan over the past three years [3].